Rola hormonoterapii w skojarzeniu z leczeniem miejscowym u chorych z rakiem prostaty o wysokim ryzyku progresji

Abstract

In the last decades, prostate cancer (PC) has become one of the most common cancer in Europe and in the United States. Hormonal therapy (HT) is the current mainstay for systemic treatment of patients with metastatic disease but lower disease patients are treated with local methods such as: radiation therapy (RT) or radical prostatectomy. However the efficacy of treatment for high-risk of disease progresion patients supported by RT and radical prostatectomy is not satisfactory. Experimental studies based on animal models showed that the idea of addition of HT to RT might improve the results of combined treatment. Outcomes from randomised trials indicated that combined treatment (HT plus RT) leads to significantly better overall and disease–specific survival results than RT alone. Nowadays the combination of long-term HT with RT is considered the treatment of choice for high-risk patients. For patients treated with radical prostatectomy the role of adjuvant HT is still controversial because there are a low number of trials which confirm the efficacy of this treatment modality.

In this review we summarize the available evidence from randomized III phase trials concerning the use of HT in both the RT and radical prostatectomy scenarios and also the most common side effects of HT.